Target
Mitogen-activated protein kinase kinase kinase kinase 1
Ligand
BDBM504036
Substrate
n/a
Meas. Tech.
Binding Assay
Ki
0.152±n/a nM
Citation
 Chan, BDaniels, BDrobnick, JGazzard, LHeffron, THuestis, MLiang, JMalhotra, SMendonca, RRajapaksa, NSiu, MStivala, CTellis, JWang, WWei, BZhou, ACartwright, MWGancia, EJones, GLainchbury, MMadin, ASeward, EFavor, DFong, KCGood, AHu, YHu, BLu, A Naphthyridines as inhibitors of HPK1 US Patent  US11034692 Publication Date 6/15/2021 
Target
Name:
Mitogen-activated protein kinase kinase kinase kinase 1
Synonyms:
HPK1 | M4K1_HUMAN | MAP4K1
Type:
PROTEIN
Mol. Mass.:
91316.07
Organism:
Homo sapiens (Human)
Description:
ChEMBL_586597
Residue:
833
Sequence:
MDVVDPDIFNRDPRDHYDLLQRLGGGTYGEVFKARDKVSGDLVALKMVKMEPDDDVSTLQKEILILKTCRHANIVAYHGSYLWLQKLWICMEFCGAGSLQDIYQVTGSLSELQISYVCREVLQGLAYLHSQKKIHRDIKGANILINDAGEVRLADFGISAQIGATLARRLSFIGTPYWMAPEVAAVALKGGYNELCDIWSLGITAIELAELQPPLFDVHPLRVLFLMTKSGYQPPRLKEKGKWSAAFHNFIKVTLTKSPKKRPSATKMLSHQLVSQPGLNRGLILDLLDKLKNPGKGPSIGDIEDEEPELPPAIPRRIRSTHRSSSLGIPDADCCRRHMEFRKLRGMETRPPANTARLQPPRDLRSSSPRKQLSESSDDDYDDVDIPTPAEDTPPPLPPKPKFRSPSDEGPGSMGDDGQLSPGVLVRCASGPPPNSPRPGPPPSTSSPHLTAHSEPSLWNPPSRELDKPPLLPPKKEKMKRKGCALLVKLFNGCPLRIHSTAAWTHPSTKDQHLLLGAEEGIFILNRNDQEATLEMLFPSRTTWVYSINNVLMSLSGKTPHLYSHSILGLLERKETRAGNPIAHISPHRLLARKNMVSTKIQDTKGCRACCVAEGASSGGPFLCGALETSVVLLQWYQPMNKFLLVRQVLFPLPTPLSVFALLTGPGSELPAVCIGVSPGRPGKSVLFHTVRFGALSCWLGEMSTEHRGPVQVTQVEEDMVMVLMDGSVKLVTPEGSPVRGLRTPEIPMTEAVEAVAMVGGQLQAFWKHGVQVWALGSDQLLQELRDPTLTFRLLGSPRLECSGTISPHCNLLLPGSSNSPASASRVAGITGL
  
Inhibitor
Name:
BDBM504036
Synonyms:
(1S,2S)—N-[8-amino-6-(2-chlorophenyl)-2,7-naphthyridin-3-yl]-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide (Compound 304) and (1R,2R)—N-[8-amino-6-(2-chlorophenyl)-2,7-naphthyridin-3-yl]-2-(1-methyl-H-pyrazol-4-yl)cyclopropane-1-carboxamide | US11034692, Compound 305
Type:
Small organic molecule
Emp. Form.:
C22H19ClN6O
Mol. Mass.:
418.879
SMILES:
Cn1cc(cn1)[C@H]1C[C@@H]1C(=O)Nc1cc2cc(nc(N)c2cn1)-c1ccccc1Cl |r|
Structure:
Search PDB for entries with ligand similarity: